Leflunomide for Triple Negative Breast Cancer

Recruiting at 2 trial locations

Overseen By Rita Vaccaro, RN

Age: 18+

Sex: Female

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Recruiting

Sponsor: Charles L Shapiro MD

Must not be taking: Investigational agents

Disqualifiers: HIV, Hepatitis B/C, untreated brain metastases, others

No Placebo Group

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial is testing the safety and effectiveness of leflunomide, a daily oral medication, in women with aggressive triple negative breast cancer. The drug aims to block a substance that helps cancer cells grow. The study focuses on women who have already tried other treatments.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, you must be at least 4 weeks from your last chemotherapy, small molecule inhibitor, biologic agent, surgery, or radiation before starting the trial.

What makes the drug Leflunomide unique for treating triple negative breast cancer?

Leflunomide is unique because it is primarily known as an immunosuppressive drug used for conditions like rheumatoid arthritis and organ transplantation, where it helps suppress the immune system and has antiviral properties. Its use in triple negative breast cancer is novel, as it may offer a different mechanism of action compared to traditional cancer treatments, potentially targeting cancer cells in a new way. ^{1 2 3 4 5}

Research Team

Joseph Sparano, MD

Principal Investigator

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

This trial is for women with metastatic triple-negative breast cancer or ER+, HER2- negative breast cancer who have undergone previous treatments. They must be over 18, not pregnant, willing to use contraception, and have a performance status of 0-2. Participants should not have had chemotherapy or radiotherapy within the last 4 weeks and must have recovered from any prior treatment side effects.

Inclusion Criteria

I am 18 years old or older.

I am taking denosumab or zoledronic.

I have had immunotherapy, but not chemotherapy.

Exclusion Criteria

I do not have any severe illnesses that could interfere with the study.

I do not have untreated brain metastases.

You have had allergic reactions to drugs similar to leflunomide or teriflunomide.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Phase I Treatment

Determine the safety, tolerability, and maximum tolerated dose of leflunomide in women with previously treated TNBC

3 months

Regular visits for dose escalation and monitoring

Phase II Treatment

Determine the efficacy of leflunomide in patients with TNBC

6 months

Regular visits for efficacy assessment using RECIST criteria

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 years

Annual visits for long-term monitoring of side effects and progression-free survival

Treatment Details

Interventions

• Leflunomide (DHODH Inhibitor)

Trial Overview The study is testing Leflunomide's safety and effectiveness in treating metastatic TNBC. It's taken orally daily and targets DHODH, an enzyme that may play a role in this type of cancer. The trial has two phases: Phase I determines the maximum tolerated dose; Phase II assesses how well it works against TNBC.

Participant Groups

Group I: Leflunomide Experimental Treatment 1 Intervention

Women with HER2-negative metastatic and/or locally advanced, inoperable breast cancer. Leflunomide tablet orally daily

Who Is Running the Clinical Trial?

Charles L Shapiro MD

Lead Sponsor

Trials

1

Recruited

50+

Joseph Sparano

Lead Sponsor

Trials

1

Recruited

50+

Findings from Research

Leflunomide shows significant immunosuppressive effects in liver and kidney transplant recipients, allowing for reductions in conventional immunosuppressive drugs like cyclosporine and prednisone without evidence of acute rejection.

The drug was well tolerated in patients with lower serum creatinine levels, but those with higher levels experienced more side effects, highlighting the importance of monitoring serum drug levels for safe and effective dosing.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Experiences with leflunomide in solid organ transplantation. Williams, JW., Mital, D., Chong, A., et al.[2022]

In a study of 32 sarcoidosis patients, leflunomide was found to be effective, with a complete or partial response in 12 out of 17 patients treated with leflunomide alone and 13 out of 15 patients receiving it alongside methotrexate.

Leflunomide was well tolerated, with only three patients experiencing nausea, and no serious adverse reactions reported, suggesting it may be a safer alternative to methotrexate for patients who cannot tolerate it.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Leflunomide for chronic sarcoidosis. Baughman, RP., Lower, EE.[2019]

Leflunomide, through its active metabolite teriflunomide, is effective in managing BK polyomavirus (BKV) infections in renal transplant recipients, with therapeutic concentrations above 40 microg/mL leading to improved clearance of the virus.

A new high-performance liquid chromatography (HPLC) method has been developed for monitoring teriflunomide levels in patients, allowing for rapid and accurate measurement to ensure effective dosing while minimizing toxicity risks.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients. Sobhani, K., Garrett, DA., Liu, DP., et al.[2021]

In a study of 7 pediatric kidney transplant patients, leflunomide effectively controlled BK virus viremia, with 67% achieving complete viral clearance, even with reduced immunosuppressive therapy.

No serious adverse effects like graft rejection or hepatotoxicity were observed, although some patients experienced mild issues like hemolytic anemia and pancreatitis, suggesting leflunomide may be a safe option for managing BK virus in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Leflunomide for BKvirus: Report of Seven Kidney-Transplanted Children. Launay, M., Baudouin, V., Guillemain, R., et al.[2022]

Leflunomide treatment in a hamster-to-mouse heart transplantation model effectively prevents the formation of xenoantibodies (XAb) and chronic rejection in the first transplanted hearts, indicating its potential as an immunosuppressive agent for xenotransplantation.

The study suggests that leflunomide induces T-independent B-lymphocyte xenotolerance, as it prevents rejection of the first grafts while allowing for chronic lesions in second grafts after treatment withdrawal, highlighting its role in modulating immune responses.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effects of a short course of leflunomide on T-independent B-lymphocyte xenoreactivity and on susceptibility of xenografts to acute or chronic rejection. Yan, Y., Verbeken, E., Yu, L., et al.[2019]

References

1. United States pubmed.ncbi.nlm.nih.gov

Experiences with leflunomide in solid organ transplantation. [2022]

2. Italy pubmed.ncbi.nlm.nih.gov

Leflunomide for chronic sarcoidosis. [2019]

3. England pubmed.ncbi.nlm.nih.gov

A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients. [2021]

4. Iran pubmed.ncbi.nlm.nih.gov

Leflunomide for BKvirus: Report of Seven Kidney-Transplanted Children. [2022]

5. United States pubmed.ncbi.nlm.nih.gov

Effects of a short course of leflunomide on T-independent B-lymphocyte xenoreactivity and on susceptibility of xenografts to acute or chronic rejection. [2019]